Drugmaker stocks gained a temporary reprieve on Thursday as U.S. President Donald Trump spared pharmaceutical products from reciprocal tariffs So this now makes the tax plan ratification, (15% made in America / 100% expensing) very important to encourage pharma mergers and acquisitions activity IMO.